Literature DB >> 21437610

Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.

I Gounaris1, E Provenzano, A L Vallier, L Hiller, M Iddawela, S Hilborne, K Taylor, P Britton, H M Earl, R Sinnatamby.   

Abstract

Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurements prior to, after 4 cycles (mid-treatment), and at the end of 8 cycles (end-treatment) of chemotherapy were available from a subset of 55 patients enrolled in Neo-tAnGo, a National Cancer Research Network (NCRN) UK neoadjuvant chemotherapy breast cancer trial. Proportional changes in longest diameter (LD) and volume as well as absolute residual size thresholds were examined for their ability to predict pCR or pCR plus minimal residual disease (pCR/MRD). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) and likelihood ratios (LRs) were calculated. Receiver-operator characteristic (ROC) curves and logistic regression models were also constructed. At mid-treatment, neither complete radiological response, nor proportional LD or volume changes were found predictive of final pCR. A small residual tumour volume (≤ 1 cm³ vs. > 1 cm³) at mid-treatment, however, was associated with pCR/MRD (P = 0.014). Sensitivity, specificity, PPV, NPV, LR+ and LR- values were 61%, 77%, 61%, 77%, 2.62 and 0.51, respectively. The area under the ROC curve was 0.689 (P = 0.03). Volume ≤ 1 cm³ at mid-treatment was found significant in a logistic regression (OR: 0.194, P = 0.011). At end-treatment, no ultrasound measurements were found predictive of pCR or pCR/MRD. In conclusion, proportional tumour size changes (the basis of the RECIST criteria) were not found predictive of good pathological response, although residual volume ≤ 1 cm³ at mid-treatment was found to be predictive of pCR/MRD. However, multiple volume and LD thresholds were examined and uncorrected P values presented, increasing the possibility of type I errors. Replication in an independent dataset is required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437610     DOI: 10.1007/s10549-011-1454-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Authors:  Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang
Journal:  Oncologist       Date:  2017-03-17

2.  Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.

Authors:  Richard G Abramson; Xia Li; Tamarya Lea Hoyt; Pei-Fang Su; Lori R Arlinghaus; Kevin J Wilson; Vandana G Abramson; A Bapsi Chakravarthy; Thomas E Yankeelov
Journal:  Magn Reson Imaging       Date:  2013-08-15       Impact factor: 2.546

3.  Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience.

Authors:  Kibo Nam; John R Eisenbrey; Maria Stanczak; Anush Sridharan; Adam C Berger; Tiffany Avery; Juan P Palazzo; Flemming Forsberg
Journal:  Radiology       Date:  2017-05-03       Impact factor: 11.105

4.  Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Deanna L Lane; Gaiane M Rauch; Stacy L Moulder; Alastair M Thompson; Roland L Bassett; Elsa M Arribas; Huong T Le-Petross; Jessica W T Leung; David A Spak; Elizabeth E Ravenberg; Jason B White; Vicente Valero; Wei T Yang
Journal:  Ultrasound Med Biol       Date:  2022-03-14       Impact factor: 2.998

5.  Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Authors:  Nazia F Jafri; David C Newitt; John Kornak; Laura J Esserman; Bonnie N Joe; Nola M Hylton
Journal:  J Magn Reson Imaging       Date:  2013-12-18       Impact factor: 4.813

6.  Prediction of treatment responses to neoadjuvant chemotherapy in breast cancer using contrast-enhanced ultrasound.

Authors:  Yunxia Huang; Jian Le; Aiyu Miao; Wenxiang Zhi; Fen Wang; Yaling Chen; Shichong Zhou; Cai Chang
Journal:  Gland Surg       Date:  2021-04

7.  A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

Authors:  E Provenzano; A-L Vallier; R Champ; K Walland; S Bowden; A Grier; N Fenwick; J Abraham; M Iddawela; C Caldas; L Hiller; J Dunn; H M Earl
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

8.  Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound.

Authors:  Xinguang Wang; Ling Huo; Yingjian He; Zhaoqing Fan; Tianfeng Wang; Yuntao Xie; Jinfeng Li; Tao Ouyang
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.